This antibody SI-B001 shows a exciting advance in hematologic care of relapsed multiple myeloma. This first-in-class antibody directly targets BCMA of myeloma malignancies, inducing antibody-dependent cellular https://izalontamab921118.pointblog.net/izalontamab-si-b001-a-encouraging-novel-protein-approach-96067606